Portfolio Companies – Page 30 – BioScience Managers

AVITA Medical Announces Nine RECELL® System Abstracts Accepted for Presentation at American Burn Association (ABA) 51st Annual Meeting

28th January 2019/in Avita Medical

RECELL System clinical benefits and cost savings featured in 26 presentations at four burn conferences in early 2019 Valencia, Calif., USA, and Melbourne, Australia, 29 January 2019 — AVITA Medical (ASX: AVH, OTCQX:AVMXY), a global regenerative medicine company,today announced that 26 abstracts highlighting theclinical and cost savings benefits of the RECELL® Autologous Cell Harvesting Device […]

Destiny Pharma awarded significant new grant funding up to £1.6 million under new UK-China AMR programme

25th January 2019/in Destiny Pharma

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN. Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma […]

Destiny Pharma notes UK 5-year action plan on AMR

24th January 2019/in Destiny Pharma

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma notes release of UK Government’s Vision and 5-year action plan to help tackle anti-microbial resistance (AMR), which includes additional investment in innovation Government’s plan consistent with Destiny Pharma’s objective of developing novel anti-infectives from its proprietary XF platform. Brighton, United Kingdom – 24 January 2019 – Destiny Pharma (AIM: […]

Notification of issue of securities

21st January 2019/in SeaDragon

For the purposes of Listing Rule 7.12.1 of the NZX Main Board Listing Rules, SeaDragon Limited (NZX:SEA) (the Company) advises that the following securities have been issued: (a) Class of security: Loan notes ISIN: Not applicable (b) Number issued: 1,000,000 (one million) (c) […]

AVITA Medical Announces Results of Extraordinary General Meeting

14th January 2019/in Avita Medical

Shareholders approve 2nd Tranche of December 2018 equity placement Valencia, Calif., USA, and Melbourne, Australia, 14 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, in accordance with ASX Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act, announce the results of the votes and the proxies received in […]

AVITA Medical Announces U.S. National Market Launch of RECELL® System

8th January 2019/in Avita Medical

Strong market response to the RECELL System approval in advance of U.S. launch with 36 burn centers actively reviewing the product or placing commercial orders Valencia, Calif., USA, and Melbourne, Australia, 8 January 2019 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that it has commenced the U.S. national […]

BioWorld Medtech – Canadian med tech, venture capital firm go global with medical implant analytics

5th January 2019/in Canary Medical

January 5, 2019 Excerpted from BioWorld MedTech, Volume 22, No.109, June 6, 2018 By David Godkin, Staff Writer The global orthopedic implants market valued at $47 billion in 2016 is expected to grow to $75 billion by 2023. To get a piece of that action, lead investors at Vancouver, B.C.-based Quark Venture Inc. are investing $10 million in Chirp data analytics […]

AmpliPhi Biosciences and C3J Therapeutics Agree to Merge

4th January 2019/in Armata Pharmaceuticals

Transaction to result in NYSE American-listed company focused on development of precisely-targeted bacteriophage therapeutics Merger combines AmpliPhi’s extensive phage library and Phase 1/2-ready asset with C3J’s expertise in synthetic phage and broad preclinical pipeline $10 million to be invested by existing C3J shareholders upon closing The companies plan to hold a joint conference call on […]

AVITA Medical Named One of the Most Innovative Companies of 2018 by PM360

21st December 2018/in Avita Medical

Valencia, Calif., USA, and Melbourne, Australia, 20 December 2018 — AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, today announced that PM360, a leading trade magazine for marketing decision makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named AVITA as one of the most innovative companies of 2018. AVITA […]

AmpliPhi Biosciences Successfully Optimizes Manufacturing Process and Scale Up for AB-SA01 Clinical Development

18th December 2018/in Armata Pharmaceuticals

AmpliPhi’s wholly owned GMP facility now capable of producing material for over 100,000 doses from each drug substance batch of AB-SA01, sufficient to support clinical trial requirements CATEGORY: Featured Tuesday, December 18, 2018 6:50 am EST SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEAM: APHB “The improved manufacturing productivity that we have achieved for AB-SA01 is […]